Download pdf
Therapeutic role of amivantamab on lung cancer: Mechanisms and applications
- 1 Southwest University of Science and Technology
* Author to whom correspondence should be addressed.
Abstract
Lung cancer is the most dangerous disease and the highest percent of cause of death. Early screening and target therapy help to improve the survival rate of development. Amivantamab, as a specific EGFR and MET double antibody, has been approved to be a specific treatment for non-small cell lung cancer (NSCLC) patients. EGFR and MET are key receptors involved in the onset and progression of NSCLC. EGFR is often altered by mutations and deletions, activates signaling pathways that regulate gene expression, and promotes metastasis through interactions with tumor and stromal cells. Its preferred partner, HER2/ERBB2, also plays an important role in cancer treatment. MET, in particular, is affected by alterations in exon 14, which leads to uncontrolled signaling due to impaired receptor degradation and promotes tumor growth. MET primarily affects older patients. This review summarizes the mechanism of NSCLC, cell structure, treatment method, and clinical test results. In the future, research on lung cancer can further optimize strategies for earlier detection and treatment of early-stage lung cancer to improve patient outcomes.
Keywords
non-small cell lung cancer, EGFR, MET, amivantamab.
[1]. World Health Organization, Lung cancer (2024), Available online at: https://www.who.int/news-room/fact-sheets/detail/lung-cancer.
[2]. Chen P, Liu Y, Wen Y and Zhou C 2022 Cancer Commun (Lond). 42 937-970
[3]. Petrini I and Giaccone G. 2022 Onco Targets Ther. 15 1197-1210.
[4]. Uribe ML, Marrocco I and Yarden Y. 2021 Cancers (Basel). 13 2748, ,
[5]. Remon J, Hendriks LEL, Mountzios G, García-Campelo R, Saw SPL, Uprety D, Recondo G and Villacampa G.J 2023 Thorac Oncol. 18 419-435
[6]. Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. 2023 Clin Lung Cancer. 24 89-97.
[7]. Vijayaraghavan S, et al. 2020 Mol Cancer Ther. 19 2044-2056
[8]. Wang K, et al. 2024 J Thorac Oncol. 19 500-506
Cite this article
Huang,X. (2024). Therapeutic role of amivantamab on lung cancer: Mechanisms and applications. Theoretical and Natural Science,61,173-177.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).